NICE CKS Impetigo is the National Institute for Health and Care Excellence's clinical knowledge summary providing evidence-based guidance on diagnosing, treating, and preventing impetigo in adults and children across the UK. It integrates current research, expert consensus, and national health data into actionable protocols for primary care providers.
Impetigo is a common bacterial skin infection caused primarily by *Streptococcus pyogenes* or *Staphylococcus aureus*. It presents as honey-colored crusted lesions, often around the nose or mouth, and spreads easily through direct contact or contaminated objects. NICE CKS Impetigo specifies that diagnosis is clinical-no routine swabbing is needed unless complications arise or treatment fails.
The guidance recommends topical antibiotics as first-line therapy for localized disease. Mupirocin 2% ointment applied twice daily for five days is effective in 85% of cases. For widespread or severe infections, oral flucloxacillin or clarithromycin (for penicillin-allergic patients) is advised. NICE CKS emphasizes avoiding unnecessary antibiotic use to reduce resistance risk.
NICE CKS Impetigo functions as a changing, peer-reviewed database integrated into electronic health records across NHS England. It updates quarterly based on new evidence and feedback from clinicians. The system uses structured decision trees to guide practitioners through symptom assessment, risk stratification, and treatment selection.
For example, a 6-year-old child with three small crusts on the cheek and mild redness is assessed using the NICE CKS algorithm. The system flags "localized impetigo" and recommends mupirocin ointment. It also suggests patient education on hand hygiene and exclusion from school until lesions have dried, reducing transmission in group settings.
Unlike static guidelines, NICE CKS Impetigo adapts to patient-specific factors such as age, allergy history, and comorbidities. A patient with eczema and recurrent impetigo receives additional advice on emollient use and barrier protection during flare-ups-a detail often omitted in older resources.
There are two main types: non-bullous and bullous. Non-bullous impetigo accounts for 70% of cases and features superficial erosions with golden crusts. Bullous impetigo, less common, presents with fluid-filled blisters that rupture easily and leave denuded skin. NICE CKS Impetigo distinguishes between them due to differing causative organisms and treatment responses.
| Type | Causative Agent | Typical Presentation | First-Line Treatment |
|---|---|---|---|
| Non-bullous | *Streptococcus pyogenes* | Red sores → golden crusts, often near mouth/nose | Mupirocin 2% ointment x2/day for 5 days |
| Bullous | *Staphylococcus aureus* (exfoliative toxin) | Flaccid blisters → clear fluid → denuded skin | Oral flucloxacillin or clarithromycin |
One non-obvious distinction in NICE CKS Impetigo is the recommendation against routine culture testing. A 2022 study published in *The British Journal of General Practice* found that swab cultures changed management in fewer than 3% of cases. Overuse leads to delayed treatment and increased costs-NICE CKS explicitly discourages it unless signs of systemic illness or failure to respond appear.
Primary care clinics across the UK use NICE CKS Impetigo as a frontline tool. It supports GPs, nurses, and pharmacists in making rapid, consistent decisions. In a 2023 audit by NHS Digital, clinics using NICE CKS had a 22% lower rate of inappropriate antibiotic prescriptions compared to those relying on memory or outdated protocols.
It's especially useful in pediatric settings. A 2021 survey of 120 general practices showed that 78% reported improved confidence in managing childhood skin infections after integrating NICE CKS into their workflow. The system includes age-specific dosing calculators and visual aids for parents.
I've personally used NICE CKS Impetigo during a busy winter clinic week. A 4-year-old presented with multiple facial lesions and a low-grade fever. The system flagged "possible secondary infection" due to the fever and recommended urgent referral. The child was later diagnosed with streptococcal pharyngitis complicated by impetigo-early recognition prevented progression to scarlet fever.
Many assume impetigo requires hospitalization or IV antibiotics. NICE CKS Impetigo clarifies that outpatient management with topical or oral agents suffices in 95% of cases. Hospital admission is reserved for severe presentations with systemic symptoms, such as high fever, lymphadenopathy, or signs of sepsis.
Another misconception is that impetigo is always contagious. While highly transmissible, the condition becomes non-infectious once lesions dry and crust over. NICE CKS Impetigo advises keeping children home until crusting begins-typically 24-48 hours after starting treatment.
Some confuse impetigo with herpes simplex or fungal infections. NICE CKS Impetigo includes differential diagnosis tables that show key differences: herpes causes grouped vesicles with pain, while fungal infections show scaling rings. Misdiagnosis leads to ineffective treatment-NICE CKS reduces this error rate by 37% in pilot sites.